Ruijie Liu1, Kyung Lee2, John Cijiang He1. 1. Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, N.Y., USA; Renal Section, James J. Peters VAMC, New York, N.Y., USA. 2. Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, N.Y., USA.
Abstract
BACKGROUND: Diabetic nephropathy (DN) is the most common cause of end-stage renal disease (ESRD) in the USA and worldwide, contributing to significant morbidity and mortality in diabetic patients. A genetic factor for the development of DN is strongly implicated, as only one third of diabetic patients eventually develop kidney disease. Growing evidence also supports an important role of epigenetic modifications in DN. SUMMARY: Multiple studies have been performed to identify risk genes and loci associated with DN. So far, only several genes and loci have been identified, none of which showed a strong association with DN. Therefore, a better study design with a larger sample size to identify rare variants and a clinically defined patient population to identify genes and loci associated with progressive DN are still needed. In addition to genetic factors, epigenetic modifications, such as DNA methylation, histone modifications and microRNAs, also play a major role in the pathogenesis of DN through a second layer of gene regulation. Although a major progress has been made in this field, epigenetic studies in DN are still in the early phase and have been limited mostly due to the heterogeneity of kidney tissue samples with multiple cells. However, rapid development of high-throughput genome-wide techniques will help us to better identify genetic variants and epigenetic changes in DN. KEY MESSAGE: Understanding of genetic and epigenetic changes in DN is needed for the development of new biomarkers and better drug targets against DN. Summarized in this review are important recent findings on genetic and epigenetic studies in the field of DN.
BACKGROUND:Diabetic nephropathy (DN) is the most common cause of end-stage renal disease (ESRD) in the USA and worldwide, contributing to significant morbidity and mortality in diabeticpatients. A genetic factor for the development of DN is strongly implicated, as only one third of diabeticpatients eventually develop kidney disease. Growing evidence also supports an important role of epigenetic modifications in DN. SUMMARY: Multiple studies have been performed to identify risk genes and loci associated with DN. So far, only several genes and loci have been identified, none of which showed a strong association with DN. Therefore, a better study design with a larger sample size to identify rare variants and a clinically defined patient population to identify genes and loci associated with progressive DN are still needed. In addition to genetic factors, epigenetic modifications, such as DNA methylation, histone modifications and microRNAs, also play a major role in the pathogenesis of DN through a second layer of gene regulation. Although a major progress has been made in this field, epigenetic studies in DN are still in the early phase and have been limited mostly due to the heterogeneity of kidney tissue samples with multiple cells. However, rapid development of high-throughput genome-wide techniques will help us to better identify genetic variants and epigenetic changes in DN. KEY MESSAGE: Understanding of genetic and epigenetic changes in DN is needed for the development of new biomarkers and better drug targets against DN. Summarized in this review are important recent findings on genetic and epigenetic studies in the field of DN.
Authors: Marine Germain; Marcus G Pezzolesi; Niina Sandholm; Amy J McKnight; Katalin Susztak; Maria Lajer; Carol Forsblom; Michel Marre; Hans-Henrik Parving; Peter Rossing; Iiro Toppila; Jan Skupien; Ronan Roussel; Yi-An Ko; Nora Ledo; Lasse Folkersen; Mete Civelek; Alexander P Maxwell; David-Alexandre Tregouet; Per-Henrik Groop; Lise Tarnow; Samy Hadjadj Journal: Diabetologia Date: 2014-12-06 Impact factor: 10.122
Authors: Bo Wang; Michal Herman-Edelstein; Philip Koh; Wendy Burns; Karin Jandeleit-Dahm; Anna Watson; Moin Saleem; Gregory J Goodall; Stephen M Twigg; Mark E Cooper; Phillip Kantharidis Journal: Diabetes Date: 2010-04-14 Impact factor: 9.461
Authors: Marpadga A Reddy; Putta Sumanth; Linda Lanting; Hang Yuan; Mei Wang; Daniel Mar; Charles E Alpers; Karol Bomsztyk; Rama Natarajan Journal: Kidney Int Date: 2013-10-02 Impact factor: 10.612
Authors: Mike Boger; Katrin Bennewitz; David Philipp Wohlfart; Ingrid Hausser; Carsten Sticht; Gernot Poschet; Jens Kroll Journal: Front Cell Dev Biol Date: 2022-07-08
Authors: Minyoung Lee; Ho Seon Park; Min Yeong Choi; Hak Zoo Kim; Sung Jin Moon; Ji Yoon Ha; ARim Choi; Young Woo Park; Jong Suk Park; Eui-Cheol Shin; Chul Woo Ahn; Shinae Kang Journal: J Clin Med Date: 2020-05-08 Impact factor: 4.241